With the recent FDA approval of Kite Pharmaceuticals CD19 targeting Chimeric Antigen Receptor (CAR) T-cell therapy (KTE-C19, Axicabtagene ciloleucel, Yescarta, Kite Pharma—a subsidiary of Gilead, F...
No takes yet. Share an insight, caveat, or question.
Hossain et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: